SMI vs SPI — picking your Swiss index ETF as an Indian investor

If you want Switzerland in your portfolio without picking individual stocks, you will choose between the country's two headline indices — the SMI and the SPI — and the choice is less obvious than it looks. The SMI (Swiss Market Index) is the famous one, the blue-chip barometer of 20 large companies. The SPI (Swiss Performance Index) is the broad one, capturing more than 200 names and over 99% of the Swiss market's free float. They sound like a simple "concentrated versus diversified" decision, but two details — how brutally concentrated the SMI really is, and whether the index counts dividends — turn this into a genuinely interesting choice for an Indian investor, where the dividend question carries tax consequences that don't apply to a Swiss local.

This guide compares the two on the things that actually matter: what each holds, how concentrated each is, the crucial price-index-versus-total-return distinction, what ETFs track them and how an Indian buys them, and the dividend-tax friction that quietly tilts the decision. By the end you should know which Swiss index belongs in your portfolio and why.

What each index actually is

The two indices come from the same exchange and overlap heavily — the SMI's 20 names are all inside the SPI — but they are built for different jobs.

	SMI (Swiss Market Index)	SPI (Swiss Performance Index)
Constituents	20 largest, most liquid	200+ (almost the whole market)
Market coverage	~75% of Swiss market cap	99%+ of free-float market cap
Includes mid/small caps	No (large caps only)	Yes
Index type	Price index (no dividends)	Total-return index (dividends reinvested)
Weight cap	Yes — capped near 18% per name	No capping
Role	Blue-chip barometer	Broad-market benchmark

The SMI is Switzerland's equivalent of the Dow or the FTSE 100 headline number — the 20 biggest, most-traded Swiss companies, the index quoted on the evening news. The SPI is closer to a total-market index: it sweeps in the 20 SMI names plus roughly 200 mid- and small-cap companies, giving you essentially the entire investable Swiss equity market in one wrapper.

The concentration trap — the SMI is three companies in a trench coat

This is the most important thing to understand before buying an SMI tracker. The SMI is not "20 companies, roughly 5% each." It is dominated by a handful of giants. Nestlé, Roche and Novartis alone make up a very large share of the index — historically well over half of it between them. The SMI applies a weight cap (no single name above roughly 18%, adjusted quarterly) precisely because these companies would otherwise breach sensible concentration limits. The cap tells you how lopsided the underlying market is.

The practical consequence: when you buy an SMI ETF, you are overwhelmingly buying consumer staples and pharma. Nestlé is staples; Roche and Novartis are pharma. Add UBS for financials and Zurich/Swiss Re for insurance, and you have most of the index. There is almost no technology, little industrial cyclicality, and the whole thing behaves like a defensive, low-beta, dividend-paying bond-proxy basket. That is not a criticism — for many investors, "defensive Swiss quality" is exactly the point. But you should buy the SMI knowing that you are making a concentrated bet on three franchises, dressed up as an index.

The SPI dilutes this. By adding 200-plus smaller names, it brings in more industrials, more specialty chemicals (think the likes of Sika, Lonza, Geberit), more genuine breadth. The big three still dominate by weight — they are huge — but the SPI is meaningfully more diversified and gives you exposure to the Swiss mid-cap and small-cap engine that the SMI ignores entirely. If you believe the interesting long-run compounding in Switzerland happens below the mega-caps, the SPI is the only one of the two that captures it. (There is also the SMIM, a dedicated mid-cap index of the 30 largest non-SMI names, if you want only the mid-caps — but for most investors the SPI is the cleaner single-fund answer.)

Price index versus total return — the detail that quietly matters

Here is a subtlety that trips up even experienced investors. The SMI is a price index — by default it does not account for reinvested dividends. The headline SMI number you see quoted reflects price moves only; the dividend yield (which on these high-payout Swiss names is substantial, ~3% across the big three) is not in the standard index figure. There is a total-return variant (often labelled SMIC) that does reinvest dividends, but the famous SMI number is the price version.

The SPI, by contrast, is a total-return index — dividends are reinvested into the index by construction. This is why, over long periods, the SPI's chart looks dramatically better than the SMI's: it is silently compounding ~3% of dividends every year that the price-only SMI throws away in its headline figure.

For an ETF buyer this matters less than it first appears, because the ETF itself — not the index — determines what happens to your dividends. An accumulating SMI ETF will reinvest the dividends it receives regardless of how the underlying index is calculated, so your total return tracks the economics, not the price-index quirk. But the distinction matters for two reasons:

1. Comparing the indices is misleading if you compare SMI (price) to SPI (total return). You are comparing a number that excludes dividends to one that includes them — apples to oranges. Always compare like for like (price-to-price, or total-return-to-total-return), or you will wildly overstate the SPI's outperformance.
2. It points to the accumulating-versus-distributing ETF choice, which for an Indian investor has a tax dimension that does not exist for a Swiss local — covered next.

The dividend-tax angle — why this is different for an Indian

A Swiss resident choosing between an accumulating and a distributing Swiss ETF mostly cares about convenience, because they reclaim the 35% Swiss withholding in full at home. For an Indian investor, the dividend treatment is a real tax variable, and it interacts with the SMI/SPI choice through yield.

The mechanics: whether the underlying Swiss dividends are reinvested by an accumulating ETF or paid out by a distributing one, those dividends are taxable in India at your slab rate (and suffer the Swiss withholding underneath, reclaimable down to the treaty 10%). Higher index yield means more dividend-tax friction and more Form 67 (being renumbered Form 44 from TY2026-27) reclaim admin each year. This is the same logic that makes high-dividend US ETFs a worse deal for Indians than for Americans, as we lay out in the best US ETFs guide.

Both Swiss indices are dividend-heavy — these are mature, high-payout companies — so neither escapes the friction. But two practical points:

• A distributing ETF forces the dividend into your hands (and onto your Indian tax return) every year, with the matching withholding and reclaim. An accumulating ETF reinvests internally, which can simplify your cash flow — though you should not assume it eliminates the Indian tax event, and the treatment of accumulating-fund income for Indian residents is a genuinely fiddly area worth confirming with an advisor.
• The SMI's defensive, high-yield tilt means more of your return comes as taxed dividends and less as clean (0% Swiss) capital gains, relative to a broader, more growth-tilted basket. Since Switzerland taxes capital gains at 0% and dividends are taxed hard at source, an Indian investor is structurally better served by the return arriving as gains than as dividends — which marginally favours breadth and growth (SPI) over the dividend-heavy mega-cap concentration (SMI).

None of this is decisive on its own, but it nudges the Indian-investor case toward the SPI more than a naive "blue chips are safer" instinct would suggest.

What you're really buying — the sector reality

It helps to see, sector by sector, what each index actually delivers, because "Swiss equities" is not a balanced basket the way "US equities" is. Switzerland's market is structurally tilted, and the SMI exaggerates that tilt while the SPI softens it.

Sector exposure	SMI (20 names)	SPI (200+ names)
Healthcare / pharma (Roche, Novartis)	Very heavy	Heavy, but diluted
Consumer staples (Nestlé)	Very heavy	Heavy, but diluted
Financials (UBS, Zurich, Swiss Re)	Moderate	Moderate
Industrials / specialty chemicals	Light	Meaningfully larger
Technology	Almost none	Still light, but present
Mid- and small-caps	None	Yes

The single most important line is the top two: between consumer staples and pharma, the SMI is overwhelmingly a defensive index. That has real portfolio consequences. It tends to hold up better than the broad world in downturns, lag in roaring bull markets, pay a high dividend, and behave with low beta — almost like a quasi-bond allocation with equity upside. If you are adding Switzerland precisely because you want a defensive, low-volatility anchor, the SMI's concentration is a feature, not a bug. If you are adding Switzerland for diversified developed-market growth, that same concentration works against you, and the SPI's broader industrial and mid-cap exposure is the better fit.

This also frames how Swiss exposure fits a global portfolio. If your core is already a US total-market or developed-world fund heavy in technology, a defensive Swiss sleeve (SMI) can be a deliberate counterweight — you are adding staples and pharma you are otherwise light on. If your aim is simply "more developed-market breadth," the SPI's wider net does that job better. Decide what role Switzerland plays in the whole before you pick the index.

The ETFs and how an Indian actually buys them

Both indices have liquid trackers on the SIX Swiss Exchange, typically from UBS and iShares. A widely cited SPI tracker is the iShares Core SPI (CHSPI) with a low total expense ratio around 0.10%; SMI trackers are available from UBS and others at comparable cost. These are CHF-denominated, SIX-listed UCITS ETFs.

The access reality for an Indian resident:

• You buy them through a global broker — Interactive Brokers, Saxo, or Swissquote — that routes to SIX. The India-fintech wrappers built around US stocks generally do not offer SIX-listed Swiss ETFs, so this typically means a global brokerage account.
• It draws on your LRS limit — the same $250,000-per-year window and TCS rules as all your overseas investing. Use the LRS/TCS calculator to size the impact.
• It is a UCITS fund, not US-domiciled — which is a structural plus. A SIX-listed Swiss UCITS ETF is not a US-situs asset, so it sits outside the US estate-tax trap that catches US-domiciled funds. (It is a Swiss-situs asset, and Switzerland levies no estate tax on the listed-share holdings of a non-resident in the way the US does.)
• Schedule FA still applies — the ETF is a foreign asset and must be disclosed every year via Schedule FA.

One more consideration: do you even need a Switzerland-only ETF? For many Indian investors, Swiss exposure already arrives inside a broad Europe or developed-world fund. A single-country Swiss ETF makes sense only if you specifically want to overweight Switzerland relative to its global market weight. If you just want "some Switzerland," a broader Europe or world fund does the job with less concentration and less single-country admin.

SMI vs SPI — the verdict

Pick the SMI if...	Pick the SPI if...
You want pure blue-chip Swiss exposure	You want the whole Swiss market
You're comfortable being heavy in Nestlé/Roche/Novartis	You want diversification across 200+ names
You want maximum liquidity and the lowest tracking error	You want mid- and small-cap upside too
Defensive, low-beta, dividend-proxy behaviour is the goal	You want a more balanced sector and growth mix

The honest summary: for most Indian investors who want broad, set-and-forget Swiss exposure, the SPI is the better default. It is genuinely diversified rather than three-companies-in-a-trench-coat, it captures the Swiss mid-cap engine the SMI ignores, and its broader, slightly-less-dividend-concentrated profile sits marginally better against the Indian tax treatment (gains taxed at a friendly 0% in Switzerland; dividends taxed hard). Choose the SMI specifically when you want the concentrated blue-chip, defensive bet — when "I want to own Nestlé, Roche and Novartis in roughly index proportions, and not much else" is precisely your thesis. That is a legitimate choice; just make it deliberately, knowing how concentrated the SMI is.

And if you find yourself wanting only the big three anyway, ask whether you should skip the index entirely and own the shares directly — at which point the ETF wrapper is just adding a fee to a bet you could make yourself. The whole Swiss menu, and how it stacks against other markets, is laid out on the markets hub.

What to actually do

• Default to a broad SPI tracker (e.g. CHSPI) for diversified, low-cost Swiss exposure, bought through a global broker that routes to SIX.
• Choose an SMI tracker only if you specifically want the concentrated blue-chip bet on Nestlé, Roche and Novartis.
• Prefer the UCITS wrapper's structural perk — no US-situs estate exposure, unlike US-domiciled funds.
• Remember the dividend tax — both indices are high-yield, so factor in the Swiss withholding reclaim, the 10% treaty rate, and your annual Form 67 credit.
• Disclose the ETF in Schedule FA every year, and remember it draws on your LRS limit.

A final practical word on cost and currency, because they apply to either choice. Both indices have trackers in the same low-cost range — roughly 0.10% to 0.20% a year — so expense ratio is not the deciding factor between them; pick on construction, not on a basis point or two. Currency, though, is unavoidable: a SIX-listed Swiss ETF prices in CHF, and your rupee return folds in the CHF/INR move between buy and sell. The Swiss franc's long-run strength and safe-haven character have historically been a tailwind for rupee returns, but you are taxed on the rupee figure and you bear the currency both ways. Neither the SMI nor the SPI escapes this — it is a property of holding a Swiss-franc asset, not of which index you choose.

The SMI-versus-SPI question looks like a footnote and is actually a real decision: concentration versus breadth, dividends versus gains, headline blue chips versus the whole market. For most Indians wanting Switzerland in the portfolio, breadth wins — but only you know whether you're buying "Switzerland" or buying "Nestlé, Roche and Novartis." Decide which, and the index picks itself.

---

This is general information, not tax or investment advice. Index methodology, ETF expense ratios, the price-versus-total-return treatment, and the tax treatment of accumulating foreign funds for Indian residents all change and have nuances — verify current details with the index provider, the ETF factsheet, and a qualified advisor before investing. Figures reflect the position as understood in early 2026.